Schott Pharma AG KGaA (XTER:1SXP) Long-Term Capital Lease Obligation : €0.0 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA Long-Term Capital Lease Obligation?

Schott Pharma AG KGaA's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.0 Mil.

Schott Pharma AG KGaA's quarterly Long-Term Capital Lease Obligation increased from Jun. 2024 (€0.0 Mil) to Sep. 2024 (€80.9 Mil) but then declined from Sep. 2024 (€80.9 Mil) to Dec. 2024 (€0.0 Mil).

Schott Pharma AG KGaA's annual Long-Term Capital Lease Obligation declined from Sep. 2022 (€71.4 Mil) to Sep. 2023 (€69.2 Mil) but then increased from Sep. 2023 (€69.2 Mil) to Sep. 2024 (€80.9 Mil).

Schott Pharma AG KGaA Long-Term Capital Lease Obligation Historical Data

The historical data trend for Schott Pharma AG KGaA's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Long-Term Capital Lease Obligation Chart

Schott Pharma AG KGaA Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

Long-Term Capital Lease Obligation

3.38

2.21

71.43

69.19

80.87

Schott Pharma AG KGaA Quarterly Data
	Sep20	Sep21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial							-	67.78	-	80.87	-

Schott Pharma AG KGaA (XTER:1SXP) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Schott Pharma AG KGaA Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Schott Pharma AG KGaA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (XTER:1SXP) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SHTPY:USA 1SXP:Italy 1SXPd:UK 1SXP:Austria

Address

Hattenbergstrasse 10, Mainz, RP, DEU, 55122

Website

https://www.schott-pharma.com

Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Executives

Dr. Jens Schulte	Supervisory Board
Andreas Reisse	Board of Directors
Ann-kristin Erkens	Supervisory Board
Dr. Almuth Steinkühler	Board of Directors
Dr. Wolfgang Wienand	Supervisory Board
Peter Goldschmidt	Supervisory Board

Schott Pharma AG KGaA Headlines

No Headlines